Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of Sunday, August 30, 2026.
Forward PE Ratio (N/A) = Close Price ($0.21) / Consensus Forward EPS ($-0.45)
FORWARD PE RATIO
N/A
PDS Biotechnology Corporation
Market Cap
$11.79M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| PDS Biotechnology Corporation (PDSB) | $11.79M | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $438.82M | N/A |
| NRC Health (NRC)vs › | $492.43M | 24.83 |
| Teladoc Health, Inc. (TDOC)vs › | $1.18B | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.23B | 7.27 |
| TransMedics Group, Inc. (TMDX)vs › | $3.06B | 59.11 |
| Doximity, Inc. (DOCS)vs › | $5.00B | 17.28 |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.40B | 21.03 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.43B | N/A |
| Chemed Corporation (CHE)vs › | $6.84B | 20.51 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus next-FY EPS
At today's $0.21 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.45 | $-0.46 – $-0.44 | 1 | n/m |
| 2027-12-31 | $-0.33 | $-0.36 – $-0.30 | 2 | n/m |
| 2028-12-31 | $-0.25 | $-0.31 – $-0.18 | 3 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
